Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02112617 · ClinicalTrials.gov registry record · NA

Phase II Study of Proton Radiation Therapy for Neuroblastoma

A NA study of Neuroblastoma and Ganglioneuroblastoma, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT02112617: Recruiting NA study of Neuroblastoma and Ganglioneuroblastoma, sponsored by Massachusetts General Hospital.

NCT02112617 is a NA study of Neuroblastoma and Ganglioneuroblastoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02112617, a NA study of Neuroblastoma and Ganglioneuroblastoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating a therapy called proton beam radiation therapy (PBRT) as a possible treatment for neuroblastoma. Neuroblastoma most commonly occurs in and around the adrenal glands, which are located at the top of the kidneys. However, it can also occur in other areas where groups of nerve cells exist, such as other areas of the abdomen, neck and near the spine. Conventional radiation therapy with photons is used as standard treatment for many patients with neuroblastic tumors. In this research study, the investigators are looking at another type of radiation called proton radiation which is known to spare surrounding tissues and organs from unnecessary radiation. Proton radiation delivers radiation to the area requiring radiation. This may reduce side effects that patients would normally experience with standard radiation therapy or other means of delivering proton radiation therapy. In this research study, the investigators are evaluating the effectiveness of using proton radiation delivered to reduce side effects associated with radiation treatment. The investigators will also be assessing the late side effects experienced by participants in each treatment group.

Primary Outcome

To describe late complications of radiation therapy delivered with proton radiotherapy in place of photon radiation for patients with neuroblastoma. Specifically, cardiac, pulmonary, gastrointestinal, endocrine, growth and second malignancies will be described.

Interventions

  • RADIATION Proton Beam Radiation Therapy

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-06
Est. Completion 2028-03
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT02112617 shows while recruiting

NCT02112617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower).

The record links to 2 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Proton Beam Radiation Therapy is the first listed.

NCT02112617 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02112617 about?

NCT02112617 is a clinical study titled "Phase II Study of Proton Radiation Therapy for Neuroblastoma". This research study is evaluating a therapy called proton beam radiation therapy (PBRT) as a possible treatment for neuroblastoma. Neuroblastoma most commonly occurs in and around the adrenal glands, which are located at the top of the kidneys. However, it can also occur in other areas where groups...

What is the current status of trial NCT02112617?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2014-06. Estimated completion is 2028-03.

What conditions does trial NCT02112617 study?

This clinical trial studies the following conditions: Neuroblastoma, Ganglioneuroblastoma.

What interventions are being tested in trial NCT02112617?

The interventions under investigation include: Proton Beam Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT02112617?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02112617 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02112617's enrollment target sits among peer trials

30 60th of 94 higher than 32 of 94 other Neuroblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02112617, the US trial registry maintained by the National Library of Medicine. NCT02112617 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.